Inhibitors of glucocorticoid receptor translocation
Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.
1. A compound of Formula (II), or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof:
wherein:
X 1 is CR 4 ;
X 2 is N;
X 3 and X 4 are independently selected from the group consisting of N and CR 4 ;
A is selected from the group consisting of bond and —CH 2 CH 2—;
B is selected from the group consisting of heterocycloalkyl, phenyl, and 5- or 6-membered heteroaryl;
wherein the heterocycloalkyl, phenyl, and heteroaryl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, heteroalkyl, heterohaloalkoxy, cycloalkyl, heterocycloalkyl, —NR a R b , tetrazoyl, —(C═O)OR c , —CN, —(C═O)R d , alkynyl, and —O(C 1 -C 4 alkylene)NR a R b ;
R 1 is selected from the group consisting of hydrogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkoxy, and —NR a R b ;
R 2 is selected from the group consisting of halogen, hydroxyl, alkoxy, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more halogen;
R 3 is alkyl substituted with one or more groups independently selected from the group consisting of halogen, hydroxyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, —NR a R b , —Oaralkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, aryl, heteroaryl, aralkyl, cycloalkyl, and heterocycloalkyl;
wherein the aryl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, alkylnyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, azidyl, —CH 2 azidyl, aryl, and aralkyl;
wherein the aryl and aralkyl are optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy; or
R 3 is selected from the group consisting of cycloalkyl, heterocycloalkyl, and 5-membered heteroaryl;
wherein the cycloalkyl, heterocycloalkyl, and heteroaryl are optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, —NR a R b , -Oaralkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, aryl, heteroaryl, aralkyl, cycloalkyl, and heterocycloalkyl;
wherein the aryl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, alkylnyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, azidyl, —CH 2 azidyl, aryl, and aralkyl;
wherein the aryl and aralkyl are optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy;
each R 4 is independently selected from the group consisting of hydrogen, halogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen and hydroxy;
each R a and R b are independently selected from the group consisting of hydrogen and alkyl;
or R a and R b taken together with the nitrogen to which they are attached form a heterocycloalkyl optionally substituted with alkyl;
R c is selected from the group consisting of hydrogen and alkyl;
R d is selected from the group consisting of aryl or heteroaryl; wherein the aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl, and alkoxy; and
R e is selected from the group consisting of alkyl and —NR a R b .
2. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
(A) X 1 is CH;
X 3 is CR 4 ; and
X 2 and X 4 are N; or
(B) X 1 and X 4 are CH; and
X 2 and X 3 are N; or
(C) X 1 and X 4 are CH;
X 2 is N; and
X 3 is CR 4 .
3. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein the compound of Formula (II) is of Formula (IIa):
wherein:
R 1 is selected from the group consisting of hydrogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkoxy, and —NR a R b ;
R 2 is selected from the group consisting of halogen, hydroxyl, alkoxy, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more halogen;
R 3 is alkyl substituted with one or more groups independently selected from the group consisting of halogen, hydroxyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, —NR a R b ,-Oaralkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, aryl, heteroaryl, aralkyl, cycloalkyl, and heterocycloalkyl;
wherein the aryl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, alkylnyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, azidyl, —CH 2 azidyl, aryl, and aralkyl;
wherein the aryl and aralkyl are optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy; or
R 3 is selected from the group consisting of cycloalkyl, heterocycloalkyl, and 5-membered heteroaryl;
wherein the cycloalkyl, heterocycloalkyl, and heteroaryl are optionally substituted with one or more groups independently selected from the group consisting of halogen, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, —NR a R b -Oaralkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, aryl, heteroaryl, aralkyl, cycloalkyl, and heterocycloalkyl;
wherein the aryl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, alkylnyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, azidyl, —CH 2 azidyl, aryl, and aralkyl;
wherein the aryl and aralkyl are optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy;
R 4 is selected from the group consisting of hydrogen, halogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen and hydroxy;
each R 5 is independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, heteroalkyl, heterohaloalkoxy, cycloalkyl, heterocycloalkyl, —NR a R b , tetrazoyl, —(C═O)OR c , —CN, —(C═O)R d , alkynyl, and —O(C 1 -C 4 alkylene)NR a R b ;
each R a and R b are independently selected from the group consisting of hydrogen and alkyl;
or R a and R b taken together with the nitrogen to which they are attached form a heterocycloalkyl optionally substituted with alkyl;
R c is selected from the group consisting of hydrogen and alkyl;
R d is selected from the group consisting of aryl or heteroaryl; wherein the aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl, and alkoxy;
R e is selected from the group consisting of alkyl and —NR a R b ; and
n is 1, 2, 3, 4, or 5.
4. The compound of claim 3 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
R 3 is alkyl substituted with one or more groups independently selected from the group consisting of halogen, hydroxyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, —NR a R b , -Oaralkyl, acetyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
wherein the aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, and aralkyl;
wherein the aralkyl is optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy.
5. The compound of claim 3 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
R 3 is heterocycloalkyl optionally substituted with one or more groups independently selected from the group consisting of alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, aryl, and aralkyl;
wherein the aralkyl is optionally substituted with one or more groups independently selected from the group consisting of alkylnyl, alkoxy, azidyl, and —CH 2 azidyl.
6. The compound of claim 3 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
n is 1.
7. The compound of claim 3 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein the compound of Formula (IIa) is of Formula (IIa-2):
wherein:
Y is is selected from the group consisting of —O—, —S—, —S(═O)—, —S(═O) 2 —, and —CH 2 —;
R 1 is selected from the group consisting of hydrogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkoxy, and —NR a R b ;
R 2 is selected from the group consisting of halogen, hydroxyl, alkoxy, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more halogen;
R 4 is selected from the group consisting of hydrogen, halogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen and hydroxyl;
R 5 is selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, heteroalkyl, heterohaloalkoxy, cycloalkyl, heterocycloalkyl, —NR a R b , tetrazoyl, —(C═O)OR c , —CN, —(C═O)R d , alkynyl, and —O(C 1 -C 4 alkylene)NR a R b ;
R 7 is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, aryl, heteroaryl, aralkyl, cycloalkyl, and heterocycloalkyl;
wherein the aryl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, alkylnyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, azidyl, —CH 2 azidyl, aryl, and aralkyl;
wherein the aryl and aralkyl are optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy;
each R a and R b are independently selected from the group consisting of hydrogen and alkyl;
or R a and R b taken together with the nitrogen to which they are attached form a heterocycloalkyl optionally substituted with alkyl;
R c is selected from the group consisting of hydrogen and alkyl;
R d is selected from the group consisting of aryl or heteroaryl; wherein the aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl, and alkoxy; and
R e is selected from the group consisting of alkyl and —NR a R b .
8. The compound of claim 7 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein the compound of Formula (IIa-2) is of Formula (IIa-2a):
wherein:
R 1 is selected from the group consisting of hydrogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkoxy, and —NR a R b ;
R 2 is selected from the group consisting of halogen, hydroxyl, alkoxy, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more halogen;
R 4 is selected from the group consisting of hydrogen, halogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen and hydroxyl;
R 5 is selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, heteroalkyl, heterohaloalkoxy, cycloalkyl, heterocycloalkyl,—NR a R b tetrazoyl, —(C═O)OR c , —CN, —(C═O)R d , alkynyl, and —O(C 1 -C 4 alkylene)NR a R b ;
R 7 is selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, aryl, heteroaryl, aralkyl, cycloalkyl, and heterocycloalkyl;
wherein the aryl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, alkylnyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, azidyl, —CH 2 azidyl, aryl, and aralkyl;
wherein the aryl and aralkyl are optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy;
each R a and R b are independently selected from the group consisting of hydrogen and alkyl;
or R a and R b taken together with the nitrogen to which they are attached form a heterocycloalkyl optionally substituted with alkyl;
R c is selected from the group consisting of hydrogen and alkyl;
R d is selected from the group consisting of aryl or heteroaryl; wherein the aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl, and alkoxy; and
R e is selected from the group consisting of alkyl and —NR a R b .
9. The compound of claim 8 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
R 7 is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, —C(═O)Otbutyl, —S(═O) 0-2 R e , acetyl, and aralkyl;
wherein the aralkyl is optionally substituted with one or more groups independently selected from the group consisting of alkylnyl, azidyl, and —CH 2 azidyl.
10. The compound of claim 3 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein the compound of Formula (IIa) is of Formula (IIa-3):
wherein:
R 1 is selected from the group consisting of hydrogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkoxy, and —NR a R b ;
R 2 is selected from the group consisting of halogen, hydroxyl, alkoxy, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more halogen;
R 4 is selected from the group consisting of hydrogen, halogen, alkyl, and cycloalkyl;
wherein the alkyl and cycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen and hydroxyl;
R 5 is selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, heteroalkyl, heterohaloalkoxy, cycloalkyl, heterocycloalkyl, —NR a R b , tetrazoyl, —(C═O)OR c , —CN, —(C═O)R d , alkynyl, and —O(C 1 -C 4 alkylene)NR a R b ;
R 8 is selected from the group consisting of aryl, heteroaryl, and heterocycloalkyl;
wherein the aryl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, —S(═O) 0-2 R e , acetyl, and aralkyl;
wherein the aralkyl is optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy;
each R a and R b are independently selected from the group consisting of hydrogen and alkyl;
or R a and R b taken together with the nitrogen to which they are attached form a heterocycloalkyl optionally substituted with alkyl;
R c is selected from the group consisting of hydrogen and alkyl;
R d is selected from the group consisting of aryl or heteroaryl; wherein the aryl and heteroaryl are optionally substituted with one or more groups independently selected from halogen, alkyl, and alkoxy; and
R e is selected from the group consisting of alkyl and —NR a R b .
11. The compound of claim 10 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
R 8 is heteroaryl optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, heteroalkyl, and aralkyl;
wherein the aralkyl is optionally substituted with one or more groups independently selected from the group consisting of alkyl and alkoxy.
12. The compound of claim 11 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
the heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, furanyl, thiophenyl, pyrrolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridinyl.
13. The compound of claim 3 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
R 5 is selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, heteroalkyl, heterohaloalkoxy, cycloalkyl, heterocycloalkyl, —NR a R b , —CN, and alkynyl.
14. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein:
R 1 is selected from the group consisting of hydrogen, methyl, ethyl, —CH 2 CH 2 OCH 3 , and —CH 2 CH 2 N(CH 3 ) 2 ;
R 2 is selected from the group consisting of chloro, fluoro, hydroxyl, —CF 3 , methoxy, ethoxy, and methyl; and
R 4 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, cyclopropyl, fluoro, chloro, and bromo.
15. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, wherein the compound of Formula (II) is selected from:
16. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, tautomer, or N-oxide thereof, and a pharmaceutically acceptable excipient.